Gilead's $375 million Calistoga buy signals shift into oncology and inflammation

Gilead Sciences is broadening its cancer and inflammatory pipeline through a $375 million acquisition of Calistoga Pharmaceuticals, with the potential for that deal to be expanded by an additional $225 million if certain milestones are met.